Clinical Trials Logo

Liver Cancer clinical trials

View clinical trials related to Liver Cancer.

Filter by:

NCT ID: NCT05430841 Recruiting - Pancreatic Cancer Clinical Trials

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 18F-AlF-FAPI positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in gastrointestinal tumors, and compared with 18F-FDG PET/CT.

NCT ID: NCT05411133 Recruiting - Pancreatic Cancer Clinical Trials

Treatment of ARB202 Advanced Gastrointestinal Cancer Patients

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

This study aims to find out: 1. The tolerability of ARB202 in adults with advanced solid gastrointestinal tumors who failed the standard treatment. People can participate if their tumor has the CDH17 marker. 2. To find out how study drug is broken down in the body 3. To know the effects of the study drug on the tumor.

NCT ID: NCT05394246 Recruiting - Liver Cancer Clinical Trials

Fluorescent-labeled IgG for Liver Tumor Detection

Start date: May 20, 2022
Phase: N/A
Study type: Interventional

This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma). The main purposes of this study include: - To validate the safety and effectiveness of using FluoAB in hepatic surgery. - To raise the surgical precision with guidance by FluoAB fluorescence imaging.

NCT ID: NCT05369988 Not yet recruiting - Liver Cancer Clinical Trials


Start date: July 1, 2022
Study type: Observational [Patient Registry]

Surgical hemostasis has become one of the fundamental principles for the advancement of surgery. The use of hemostatic agents is standard in many surgical specialties, although the lack of consensus or standardized classifications to determine intraoperative bleeding has led to their inappropriate selection on many occasions. The recommendations of international organizations highlight the need for a bleeding severity scale validated in clinical studies that allows selecting the hemostatic agent that best suits each case.

NCT ID: NCT05369650 Recruiting - Liver Cancer Clinical Trials

To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients

Start date: July 27, 2019
Phase: N/A
Study type: Interventional

All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1, lidocaine group 1.5, and lidocaine group 2, 1% lidocaine 1.5 mg/kg was intravenously infused with a micropump after anesthesia induction, and the infusion was completed within 10 minutes according to the ideal body weight, and then continued for 1% lidocaine was infused at 1 mg/kg.h, 1.5 mg/kg.h and 2 mg/kg.h respectively until the end of the operation. In the placebo group, the same volume of normal saline was used instead.

NCT ID: NCT05366829 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.

NCT ID: NCT05363605 Recruiting - Breast Cancer Clinical Trials

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Start date: May 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human, Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, dosimetry, biodistribution, and PK of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase 1 consists of five multiple dose escalation cohorts. Phase 2 consists of two tumour-specific cohorts and one basket cohort.

NCT ID: NCT05360420 Not yet recruiting - Liver Cancer Clinical Trials

Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Due to different etiologies, diagnosis and treatment of HCC in China is different from that in Western countries.US is an important screening method for HCC in patients with liver cirrhosis. CEUS, as an enhanced imaging method based on US, has the advantages of convenience, non-radiation, low cost, short examination time, and the diagnostic performance of HCC is comparable to that of CECT, CEMRI, and hepatobiliary-specific MRI. It is of great significance to consider the cost-effectiveness of each examination based on the principle of cost minimization. Therefore, we propose immediate CEUS examination for suspicious lesions ≤2 cm screened by US, and determine the diagnostic process of further diagnostic methods based on the CEUS results. The aim of this study is to establish a screening and diagnosis process for HCC ≤2 cm suitable for China considering time effect, economic effect and diagnostic efficiency.

NCT ID: NCT05343832 Enrolling by invitation - Liver Cancer Clinical Trials

Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients

Start date: November 29, 2021
Study type: Observational

This trail is a multi-center,prospective observational study aimed to detect early-stage Hepatocellular Carcinoma by a Novel Blood-based DNA Methylation Assay(named Genetron HCC Methylation PCR Kit ). The accuracy of the kit will also be evaluated . The trail will be enroll approximately 4816 participants, including participants with HCC or benign diseases, and high risk factors for liver cancer.

NCT ID: NCT05342350 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Prospective Observational Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy

Start date: April 15, 2022
Study type: Observational [Patient Registry]

This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.